BCLSI
DRNA

Bain Capital Life Sciences Investors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,080,237
Closed -$62.1M – 36
2021
Q3 		$62.1M Hold
3,080,237
– – 3.85% 9
2021
Q2 		$115M Hold
3,080,237
– – 7.53% 4
2021
Q1 		$78.8M Hold
3,080,237
– – 4.46% 7
2020
Q4 		$67.9M Sell
3,080,237
-1,000,000
-25% -$22M 4.26% 6
2020
Q3 		$73.4M Hold
4,080,237
– – 6.84% 4
2020
Q2 		$104M Hold
4,080,237
– – 10.85% 3
2020
Q1 		$75M Hold
4,080,237
– – 12.68% 3
2019
Q4 		$89.9M Sell
4,080,237
-3,250,000
-44% -$65.4M 13.41% 3
2019
Q3 		$105M Hold
7,330,237
– – 27.1% 2
2019
Q2 		$115M Sell
7,330,237
-1,600,000
-18% -$21.8M 58.64% 1
2019
Q1 		$131M Hold
8,930,237
– – 52.31% 1
2018
Q4 		$95.5M Hold
8,930,237
– – 32.62% 1
2018
Q3 		$136M Hold
8,930,237
– – 30.93% 1
2018
Q2 		$109M Hold
8,930,237
– – 34.28% 1
2018
Q1 		$85.4M Hold
8,930,237
– – 50.34% 1
2017
Q4 		$80.6M Buy
+8,930,237
New +$65.7M 52.91% 1

Other funds holding DRNA

CAM
Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Bain Capital Life Sciences Investors's DRNA Position: Q4 2021 in Review

Bain Capital Life Sciences Investors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 3,080,237 shares — an estimated $62.1M sold.

Bain Capital Life Sciences Investors first reported a position in DRNA in Q4 2017 and held it in 16 quarters. The position peaked at $136M in Q3 2018. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

  • Bain Capital Life Sciences Investors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Bain Capital Life Sciences Investors sold 3,080,237 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $62.1M.
  • Bain Capital Life Sciences Investors first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2017 and held it in 16 quarters.
  • Bain Capital Life Sciences Investors's Dicerna Pharmaceuticals, Inc. position peaked at $136M in Q3 2018.
  • 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2021, filed 14 Feb 2022.